Details of the Drug Combinations

General Information of This Drug (ID: DMZC1HS)

Drug Name
Ivacaftor   DMZC1HS
Synonyms Kalydeco (TN)
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Ivacaftor + Ruxolitinib DCHJLUQ Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [2]
------------------------------------------------------------------------------------
3 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ciprofloxacin XR + Ivacaftor DCSUHW4 Ciprofloxacin XR Cystic Fibrosis [3]
Lumacaftor + Ivacaftor DCD6K9J Lumacaftor Cystic Fibrosis [4]
VX-661 + Ivacaftor DCSJERV VX-661 Cystic Fibrosis [5]
------------------------------------------------------------------------------------
1 Approved Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Lumacaftor + Ivacaftor DCEIVC9 Lumacaftor Cystic fibrosis; Acute lung injury [6]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4342).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 ClinicalTrials.gov (NCT02015507) An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
4 ClinicalTrials.gov (NCT01768663) A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
5 ClinicalTrials.gov (NCT02953314) A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
6 FDA Drug Development and Drug Interactions